Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 152, Issue 6, pp 731–733 | Cite as

Dimebon Reduces the Levels of Aggregated Amyloidogenic Protein Forms in Detergent-Insoluble Fractions In Vivo

  • A. A. UstyugovEmail author
  • T. A. Shelkovnikova
  • V. S. Kokhan
  • I. V. Khritankova
  • O. Peters
  • V. L. Buchman
  • S. O. Bachurin
  • N. N. Ninkina
Article

Aggregation of proteins liable to assembling into fi brils with subsequent formation of amyloid incorporations is an important component in the pathogenesis of many neurodegenerative diseases. Dimebon, a Russian drug, reduces the content of detergent-insoluble fi brillar forms of synuclein, the main protein component of pathological incorporations in neurons of transgenic mouse strain used in the study.

Keywords

dimebon neurodegeneration synucleins transgenic animals 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. O. Bachurin, A. A. Ustyugov, O. Peters, et al., Dokl. Ross. Akad. Nauk, Biochim. Biophys., 428, No. 2, 262-265 (2009).Google Scholar
  2. 2.
    V. L. Buchman, J. Adu, L. G. Pinõn, et al., Nat. Neurosci., 1, No. 2, 101-103 (1998).PubMedCrossRefGoogle Scholar
  3. 3.
    V. L. Buchman, H. J. Hunter, L. G. Pinõn, et al., J. Neurosci., 15, No. 18, 9335-9341 (1998).Google Scholar
  4. 4.
    R. S. Doody, S. I. Gavrilova, M. Sano, et al., Lancet, 372, 207-215 (2008).PubMedCrossRefGoogle Scholar
  5. 5.
    K. Kieburtz, M. P. McDermott, T. S. Voss, et al., Arch. Neurol., 67, No. 2, 154-160 (2010).PubMedCrossRefGoogle Scholar
  6. 6.
    P. T. Lansbury and H. A. Lashuel, Nature, 443, 774-779 (2006).PubMedCrossRefGoogle Scholar
  7. 7.
    N. Ninkina, O. Peters, S. Millership, et al., Hum. Mol. Genet., 18, No. 10, 1779-1794 (2009).PubMedCrossRefGoogle Scholar
  8. 8.
    D. M. Skovronsky, V. M. Lee, and J. Q. Trojanowski, Ann. Rev. Pathol., 1, 151-170 (2006).CrossRefGoogle Scholar
  9. 9.
    J. W. Steele, S. H. Kim, J. R. Cirrito, et al., Mol. Neurodegener., 4, 51 (2009).PubMedCrossRefGoogle Scholar
  10. 10.
    J. Wu, Q. Li, and I. Bezprozvanny, Ibid., 3, 15 (2008).Google Scholar
  11. 11.
    M. Yamashita, T. Nonaka, T. Arai, et al., FEBS Lett., 583, No. 14, 2419-2424 (2009).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2012

Authors and Affiliations

  • A. A. Ustyugov
    • 1
    Email author
  • T. A. Shelkovnikova
    • 1
  • V. S. Kokhan
    • 1
  • I. V. Khritankova
    • 1
  • O. Peters
    • 2
  • V. L. Buchman
    • 2
  • S. O. Bachurin
    • 1
  • N. N. Ninkina
    • 1
    • 2
  1. 1.Department of Medical and Biological Chemistry, Institute of Physiologically Active SubstancesRussian Academy of Sciences, ChernogolovkaMoscowRussia
  2. 2.Department of Medical and Biological Chemistry, Institute of Physiologically Active SubstancesRussian Academy of Sciences, Chernogolovka, Cardiff UniversityCardiffUK

Personalised recommendations